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One of today’s most powerful technologies in biomedical research—the creation of mutant mice by
gene targeting in embryonic stem (ES) cells—was finally celebrated in this year’s Nobel Prize in Med-
icine. The history of how ES cells were first discovered and genetically manipulated highlights the
importance of collaboration among scientists from different backgrounds with a shared vision.Knockout mice have had a profound
impact on biomedical research. They
have allowed us to interrogate the
real-life function of specific genes in
the context of the adult organism and
the developing embryo. They have
also enabled us to generate mouse
models of many human diseases. The
technologies essential for making
these advances were celebrated by
this year’s Nobel Prize in Medicine to
Mario Capecchi, Martin Evans, and
Oliver Smithies for ‘‘their discoveries
of principles for introducing specific
gene modifications in mice by the use
of embryonic stem cells.’’ When these
three scientists step forward to receive
the prize, they will represent a cadre of
other tenacious and innovative re-
searchers whose work was essential
to the final story. Many of these un-
sung heroes were extraordinarily gen-
erous in sharing their discoveries so
that their tools and ideas could rapidly
spread throughout the scientific com-
munity. This meant that, over a rela-
tively short period of time, research
into some quite esoteric topics came
to profoundly impact almost every field
of biology and medicine.
There were two breakthroughs nec-
essary for the creation of genetically
engineered mice. One was the isola-
tion of pluripotential mouse embryonic
stem (ES) cells that can differentiate
into all cell types of the body, including
germ cells, when introduced into pre-
implantation stage embryos. The other
was the technique of ‘‘gene targeting,’’
in which homologous recombination
between a vector introduced into the
ES cells and chromosomal DNA is
used to make specific modifications
of a particular endogenous gene. One
breakthrough without the other wasnot enough; while ES cells have given
important insights intomammalian em-
bryology, and are likely to revolutionize
regenerative medicine in humans,
without efficient and accurate gene
targeting they could not have been
used for manipulating the germline.
That said, most of this commentary
will focus on ES cells because of their
relevance tomammaliandevelopment,
a topic frequently encountered in the
pages of this journal.
To understand the history of ES
cells, we need to go back to the early
1950s. At this time Leroy Stevens,
working at The Jackson Laboratory,
Bar Harbor, discovered that the 129
line of inbred mice had a low incidence
of a rather obscure tumor known as
a testicular teratocarcinoma (Solter,
2006). This tumor contains a disorga-
nized mixture of many tissues such
as bone, gut, neuroepithelium, and
skin, and a population of small, undif-
ferentiated cells known as embryonal
carcinoma (EC) cells. Stevens ob-
tained evidence that the tumors arise
from the germ cells of the testis and
showed that modifier genes—one of
which (Ter) has been recently identi-
fied (Youngren et al., 2005)—promote
this transformation. His work was
closely aligned with that of anM.D. pa-
thologist, Barry Pierce, who was fasci-
nated by teratocarcinomas and the
controversies then surrounding their
origin. In 1964, while at the University
of Michigan, Ann Arbor, Pierce did
a crucial experiment; he demonstrated
that a single EC cell injected into a host
would give rise to a new teratocarci-
noma, while differentiated cells from
the tumor would not (Kleinsmith and
Pierce, 1964). This strongly supported
the idea that EC cells are ‘‘pluripotentDevelopmental Cell 13,stem cells’’ within the tumor, since
they can both self-renew and give
rise to a whole range of different cell
types. In parallel experiments, Stevens
and Davor Solter and his colleagues in
Yugoslavia showed that transplant-
able teratocarcinomas containing EC
cells can be derived by grafting early
postimplantation mouse embryos into
host mice. The conclusion from all
these studies was that normal early
embryos contain, if only transiently,
a population of pluripotential cells
that might be isolated and manipu-
lated (Solter et al., 1980).
The scientists working with terato-
carcinomas generously sent samples
to many laboratories interested in
developing in vitro conditions in which
EC cells would grow and differentiate.
Martin Evans in University College,
London, was among those who ob-
tained the cells, and Gail Martin, then
his postdoctoral fellow, was particu-
larly successful at culturing them; she
showed that a clonal line derived from
a single EC cell would differentiate
into many cell types. Her observation
that EC cells in culture give rise to
structures known as ‘‘embryoid bod-
ies’’ resembling early mouse embryos
was hugely influential. It promoted the
idea that EC (and later ES) cells could
be used asmodels of early mammalian
development (Martin, 1980). Work with
EC cells also inspired the idea that it
might be possible to induce them to
differentiate into normal tissues by ex-
posing them to morphogenetic signals
present in embryos. This could be ac-
complished, the ideawent, by injecting
them into a host blastocyst to generate
a chimera.Heroic effortsweremadeby
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this goal, but the contribution of cul-
tured EC cells to tissues was low—
none made germ cells and all retained
tumor-forming capacity. One explana-
tion is that EC cells harbor irreversible
malignant mutations. In addition, it is
possible that they more closely resem-
ble stemcells recently derived from the
postimplantation epiblast (EpiSCs),
which do not contribute to chimeras,
than ES cells from the inner cell mass
do (Brons et al., 2007; Tesar et al.,
2007).
The work with EC cells led a number
of laboratories to test whether pluripo-
tent stem cells could be derived from
normal blastocysts. In 1981, two
groups reported success. One was
that of Martin Evans, who had moved
to the Department of Genetics in Cam-
bridge and recruited two exceptional
graduate students, Elizabeth Robert-
son and Allan Bradley. They collabo-
rated with Matthew Kaufman in the
Anatomy Department who had exten-
sive experience in mouse embryology
and knew how to use implantation
delay to boost the number of cells in
the inner cell mass, a trick that was
thought to increase the efficiency of
the derivation process (Evans and
Kaufman, 1981). Completely indepen-
dently, and using different methods,
Gail Martin also generated pluripotent
stem cells in her laboratory at UCSF.
It was Gail who coined them ‘‘embry-
onic stem’’ cells and who formally
proved that individual ES cells are
pluripotent (Martin, 1981).
The next challenge was to show that
ES cells would contribute to the germ-
line in chimeras and would retain this
ability even after genetic manipulation.
Bradley and Robertson streamlined
methods for injecting ES cells into
blastocysts and created the first ES-
derived mice (Bradley et al., 1984).
The Cambridge group also conceived
the idea of using retroviruses to make
random insertional mutations in their
cells and so generated the first mutant
lines of mice from ES cells (Robertson
et al., 1986). Cloning the retroviral
insertion site in one of these lines later
led to the discovery of the nodal gene,
which is central to vertebrate develop-
ment (Zhou et al., 1993). They also
selected ES cells with a retroviral770 Developmental Cell 13, December 2insertion in the Hprt locus and
used them to make null mutant mice,
although unfortunately these mice
did not, as expected, show the
neurological symptoms of the human
Lesch-Nyhan disorder (Kuehn et al.,
1987).
Although retroviruses are a powerful
tool for both disrupting and tagging
genes, homologous recombination us-
ing targeting vectors allows very spe-
cific modifications to be engineered
into the genome. The driving force
behind this part of the story came
from the research of Mario Capecchi
and Oliver Smithies. Although homolo-
gous recombination in eukaryotic cells
had been demonstrated much earlier
in yeast, the idea that exogenous
DNA could recombine accurately with
the mouse genome was initially con-
sidered with great skepticism. Smith-
ies carried out his early studies at the
University of Wisconsin, driven by the
desire to repair mutations in the human
globin gene associated with thalasse-
mia (Smithies et al., 1985). As a molec-
ular biologist, Capecchi came to the
problem by a different route. Working
at the University of Utah, his initial
approach was tomicroinject DNAmol-
ecules that carried a selectable marker
directly into the nucleus of cultured
cells and ask how they recombined
and integrated as concatamers into
the chromosomes (Capecchi, 1980).
All along, both Capecchi and Smithies
saw the huge potential of ES cells as
a route to generating specific muta-
tions in the mammalian germline. In
addition, Capecchi visited Cambridge
to learn first-hand the techniques
developed there. The first demonstra-
tions of homologous recombination
in ES cells made use of the Hprt
gene. Smithies and his postdoctoral
fellow Thomas Doetschman repaired
a spontaneous Hprt mutation in
ES cells (Doetschman et al., 1987)
while Kirk Thomas and Mario Capec-
chi inserted a specific mutation into
the wild-type locus (Thomas and Ca-
pecchi, 1987). The Capecchi lab also
pioneered the methods now widely
used for selecting cells in which ho-
mologous recombination has oc-
curred from the much larger popula-
tion in which insertion of the targeting
DNA is random.007 ª2007 Elsevier Inc.The early successes with homolo-
gous recombination in ES cells
opened the floodgates to genetic
manipulation of the mouse. We now
have an impressive array of tools for
designing anything from simple gene
deletions to sophisticated conditional
mutations and reporter alleles for
following cell behavior and lineages.
The rapid dissemination and growth
of these powerful technologies is due
in large part to the generosity and en-
thusiasm with which many of the early
leaders shared their cells, discoveries,
and ideas. The 2007 Nobel Prize in
Medicine, while of necessity awarded
to only three, will recognize all those
who helped combine genetics and
embryology to address fundamental
problems in mammalian biology and
medicine.
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